molecular imaging techniques, molecular imaging agents and contrast agents, radiomics or imaging biomarkers, and related technologies. The underlying technologies may be refined and optimized during testing in response to research questions or clinical needs.
The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
The membership panel is a list of chartered members only.
- Evaluation of improvements in technologies underlying medical imaging systems, as well as studies of available medical imaging systems to evaluate novel medical applications.
- Pre-clinical, Phase-I, and -II clinical trials of medical imaging systems and accessories, including MRI, MRS, optical, PET, PET/CT, fMRI, photoacoustic, DTI, nuclear medicine, ultrasound, multimodality, etc. and their associated contrast agents.
- Prediction, selection, and monitoring of therapeutic response based on imaging studies, with or without exogenous agents, using one or more modalities, especially for multi-temporal investigations to measure changes relative to a pretreatment baseline.
- Optimization of imaging systems and modification of diagnostic methods for use in: screening; characterizing physiological effects, and assessing risk.
- Image-guided interventions in integrated diagnostic and therapeutic systems.
- In vivo strategies and methods for characterizing tissue, and distinguishing between normal and pathologic states, based on estimates of biophysical, biomechanical, bioelectrical, biochemical, metabolic, perfusion/diffusion, or other properties.
- Development of surrogate endpoints based on quantitative imaging for use in clinical trials of medical devices, pharmaceuticals, biologics and other therapeutic interventions.
- Prediction, selection and monitoring therapeutic response by administering agents and imaging, to detect the location, amount, and fate of the agent in normal and diseased tissues.
- Diagnosis of functional disorders and classification of tissue as normal or pathologic based on exogenous agents that may be tailored to specific cellular processes or genetic expressions.
Shared Interests and Overlaps
There are shared interests with Biomedical Imaging Technology Study Sections A and B (BMIT A) and (BMIT B) in the development of medical imaging systems and technologies in pre-clinical and early clinical studies. Grant applications that focus on the design, development, implementation and integration of imaging systems and technologies may be assigned to BMIT study sections. Applications that focus on optimization and validation of the imaging systems and technologies towards diagnosis and staging of diseases, assessment of functional disorders, prediction or monitoring of therapeutic responses, or stratification of patients for therapeutic options or image guided interventions, may be assigned to MEDI study section.
There are shared interests with Neuroscience and Ophthalmic Imaging Technologies study section (NOIT) in the content of developing and applying imaging systems and technologies to study neuroscience and ophthalmic problems. Grant applications with central theme of studying fundamental neuroscience context while utilizing imaging systems and technologies may be assigned to NOIT. Applications that focus on refinement, optimization or validation of imaging systems and technologies and applying the imaging technologies to the neuroscience applications may be reviewed in MEDI study section.
There are shared interests with Clinical Molecular Imaging and Probe Development Study Section (CMIP) in the development of image agents and surrogate endpoints and validation of these agents in pre-clinical and clinical studies. Grant applications that focus on the compound screening, synthesis, development, biodistribution, and pharmacokinetics of imaging agents may be assigned to CMIP. Applications that focus on validation and applications of the imaging systems or imaging agents and their use in the diagnosis of functional disorders, image guided interventions, or prediction, selection, or monitoring of therapeutic response may be assigned to MEDI study section.
There are shared interests with the Clinical Oncology Study Section (CONC) reviews applications in the use of imaging biomarkers for clinical research and therapeutic trials. Grant applications that focus on determining or validating therapeutic use of drugs, radiation, surgery, and/or biological agents and cancer biomarkers for cancer detection, progression and response to therapy may be assigned to CONC. Applications that focus on validation and applications of the imaging systems, methodologies and their performance in diagnosis of cancer or monitoring progression and response to therapy may be assigned to MEDI study section.
There are shared interests with the Radiation Therapeutics and Biology Study Section (RTB) in the use of image guided therapies in the treatment of oncological patients. Grant applications focusing on the biological changes and therapeutic interactions due to administration of ionizing radiation, radionuclides, electromagnetic radiation, heat or other radiation therapeutics may be assigned to RTB Study Section. Applications that focus on imaging technology optimization for targeting, delivery of the drugs, distinguishing tumor from tissue injuries may assigned to MEDI study section.
There are shared interests with the Clinical Neuroscience and Neurodegeneration study section (CNN) for imaging detection, diagnosis, and functional assessment of neurodegenerative and neurocognitive diseases. Grant applications focus on studying the etiology, pathophysiology, consequences and the development of therapeutic strategies may be more appropriate for CNN study section. Applications that focus on refining or optimizing imaging systems and methodologies may be assigned to MEDI study section.